 BEVERLY, Mass., June 01, 2021 GLOBE NEWSWIRE -- LexaGene Holdings, Inc., TSX-V: LXG; OTCQB: LXXGF the Company, a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it is taking steps to list its common shares on the Nasdaq Capital Market with the goal of submitting its application prior to the end of 2021. A successful listing on the Nasdaq will make the Companys shares more accessible to retail and institutional investors in the United States and internationally as well as increase share liquidity. The Nasdaq is the Companys preferred Exchange as it hosts the best biotech and life science companies in the world. 